FDA told telehealth seller TRYM Health its website claims for compounded semaglutide and tirzepatide are false and misleading, making the drugs misbranded.
What happened
FDA reviewed the website trymhealth.com in August 2025 and found it offering compounded drug products, including semaglutide and tirzepatide. The site said the products were "Clinically Proven to Work" and contained "the same active ingredient as" Mounjaro, ZepBound, Ozempic and Wegovy. FDA said those claims imply the compounded products are the same as FDA-approved drugs when they are not, so the products are misbranded (misbranded means the labeling or promotion is false or misleading).
What FDA found
The website's claims for compounded semaglutide and tirzepatide are false or misleading, which misbrands the drugs.
FDCA section 502(a) [21 U.S.C. § 352(a)]Advertising and promotion of a compounded drug that is false or misleading misbrands that drug.
FDCA section 502(bb) [21 U.S.C. § 352(bb)]Saying the products contain the same active ingredient as Mounjaro, ZepBound, Ozempic and Wegovy implies they are the same as FDA-approved products, which they are not.
FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]Shipping these misbranded drugs across state lines is a prohibited act.
FDCA section 301(a) [21 U.S.C. § 331(a)]Receiving misbranded drugs in interstate commerce, or delivering them, is also prohibited.
FDCA section 301(c) [21 U.S.C. § 331(c)]
What FDA wants
FDA tells the company to stop using the cited claims immediately and to send the Office of Compounding Quality and Compliance a written response within 15 working days describing each corrective step and how it will prevent repeat violations. If the company believes it is not in violation, it must explain why and provide supporting information.
Who should pay attention
- telehealth companies selling compounded GLP-1 drugs online
- compound pharmacies that supply or advertise through such sites
- marketing and regulatory reviewers of prescription drug websites
This is a summary. Read the original letter on fda.gov.